{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:43:16Z","timestamp":1791286996520,"version":"4.1.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain, Behavior, & Immunity - Health"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bbih.2025.101048","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:12:23Z","timestamp":1751429543000},"page":"101048","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Prevalence and treatment response of neuropsychiatric disorders in mast cell activation syndrome"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6484-1691","authenticated-orcid":false,"given":"Leonard B.","family":"Weinstock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence B.","family":"Afrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Reiersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Brook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Blitshteyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Ehrlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill R.","family":"Schofield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Kinsella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Dempsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9005-2749","authenticated-orcid":false,"given":"Gerhard J.","family":"Molderings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbih.2025.101048_bib1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.trsl.2016.01.003","article-title":"Mast cell activation disease and the modern epidemic of chronic inflammatory disease","volume":"174","author":"Afrin","year":"2016","journal-title":"Transl. Res."},{"key":"10.1016\/j.bbih.2025.101048_bib2","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bbi.2015.07.002","article-title":"Mast cell activation disease: an underappreciated cause of neurologic and psychiatric symptoms and diseases","volume":"50","author":"Afrin","year":"2015","journal-title":"Brain Behav. Immun."},{"issue":"3","key":"10.1016\/j.bbih.2025.101048_bib3","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3109\/07853890.2016.1161231","article-title":"Often seen, rarely recognized: mast cell activation disease--a guide to diagnosis and therapeutic options","volume":"48","author":"Afrin","year":"2016","journal-title":"Ann. Med."},{"issue":"3","key":"10.1016\/j.bbih.2025.101048_bib4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.amjms.2016.12.013","article-title":"Characterization of mast cell activation syndrome","volume":"353","author":"Afrin","year":"2017","journal-title":"Am. J. Med. Sci."},{"issue":"2","key":"10.1016\/j.bbih.2025.101048_bib5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1515\/dx-2020-0005","article-title":"Diagnosis of mast cell activation syndrome: a global \"consensus-2\"","volume":"8","author":"Afrin","year":"2020","journal-title":"Diagnosis (Berl)"},{"key":"10.1016\/j.bbih.2025.101048_bib6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ijid.2020.09.016","article-title":"Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome","volume":"100","author":"Afrin","year":"2020","journal-title":"Int. J. Infect. Dis."},{"issue":"12","key":"10.1016\/j.bbih.2025.101048_bib7","doi-asserted-by":"crossref","first-page":"29069","DOI":"10.3390\/ijms161226151","article-title":"Mast cell-mediated mechanisms of nociception","volume":"16","author":"Aich","year":"2015","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.bbih.2025.101048_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: proposed diagnostic criteria","volume":"126","author":"Akin","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"issue":"11","key":"10.1016\/j.bbih.2025.101048_bib9","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/archinte.165.11.1286","article-title":"Restless legs syndrome prevalence and impact: REST general population study","volume":"165","author":"Allen","year":"2005","journal-title":"Arch. Intern. Med."},{"issue":"4","key":"10.1016\/j.bbih.2025.101048_bib10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000097202","article-title":"Passage of cytokines across the blood-brain barrier","volume":"2","author":"Banks","year":"1995","journal-title":"Neuroimmunomodulation"},{"issue":"6","key":"10.1016\/j.bbih.2025.101048_bib11","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/jamapsychiatry.2022.0685","article-title":"Prevalence, comorbidity, and sociodemographic correlates of psychiatric disorders reported in the all of us research program","volume":"79","author":"Barr","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.bbih.2025.101048_bib12","article-title":"Tinnitus prevalence, associated characteristics, and related healthcare use in the United States: a population-level analysis","volume":"29","author":"Batts","year":"2024","journal-title":"Lancet Reg. Health Am."},{"key":"10.1016\/j.bbih.2025.101048_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1471-2474-8-27","article-title":"An internet survey of 2,596 people with fibromyalgia","volume":"8","author":"Bennett","year":"2007","journal-title":"BMC Muscoskelet. Disord."},{"issue":"6","key":"10.1016\/j.bbih.2025.101048_bib14","doi-asserted-by":"crossref","first-page":"570","DOI":"10.7861\/clinmed.2022-0402","article-title":"The diagnosis of fibromyalgia syndrome","volume":"22","author":"Berwick","year":"2022","journal-title":"Clin. Med."},{"issue":"1","key":"10.1016\/j.bbih.2025.101048_bib15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0162-3109(99)00046-6","article-title":"Inhibition of mouse mast cell proliferation and proinflammatory mediator release by benzodiazepines","volume":"43","author":"Bidri","year":"1999","journal-title":"Immunopharmacology"},{"issue":"8","key":"10.1016\/j.bbih.2025.101048_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2017.137","article-title":"Neuroimaging evidence of brain abnormalities in mastocytosis","volume":"7","author":"Boddaert","year":"2017","journal-title":"Transl. Psychiatry"},{"issue":"4","key":"10.1016\/j.bbih.2025.101048_bib17","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/head.13281","article-title":"The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies","volume":"58","author":"Burch","year":"2018","journal-title":"Headache"},{"issue":"1","key":"10.1016\/j.bbih.2025.101048_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/cap.2014.0084","article-title":"Clinical evaluation of youth with pediatric acute-onset neuropsychiatric syndrome (PANS): recommendations from the 2013 PANS consensus conference","volume":"25","author":"Chang","year":"2015","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.bbih.2025.101048_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114654","article-title":"Unravelling the role of Interleukin-12 in neuroinflammatory mechanisms: pathogenic pathways linking neuroinflammation to neuropsychiatric disorders","volume":"156","author":"Chauhan","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.bbih.2025.101048_bib20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12969-021-00493-6","article-title":"Juvenile primary fibromyalgia syndrome: epidemiology, etiology, pathogenesis, clinical manifestations and diagnosis","volume":"19","author":"Coles","year":"2021","journal-title":"Pediatr. Rheumatol. Online J."},{"issue":"3","key":"10.1016\/j.bbih.2025.101048_bib21","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/diagnostics8030066","article-title":"A brief questionnaire to assess post-exertional malaise","volume":"8","author":"Cotler","year":"2018","journal-title":"Diagnostics"},{"issue":"2","key":"10.1016\/j.bbih.2025.101048_bib22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1254\/jphs.08028FP","article-title":"Suppression of histamine signaling by probiotic Lac-B: a possible mechanism of its anti-allergic effect","volume":"107","author":"Dev","year":"2008","journal-title":"J. Pharmacol. Sci."},{"issue":"11","key":"10.1016\/j.bbih.2025.101048_bib23","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s11910-023-01307-w","article-title":"Hypermobility spectrum disorders and mast cell activation syndrome as migraine comorbidities","volume":"23","author":"Blitshteyn","year":"2023","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"10289","key":"10.1016\/j.bbih.2025.101048_bib24","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1016\/S0140-6736(21)00392-5","article-title":"Nociplastic pain: towards an understanding of prevalent pain conditions","volume":"397","author":"Fitzcharles","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bbih.2025.101048_bib25","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3390\/nu11020344","article-title":"Enhancement of exercise performance by 48 hours, and 15-Day supplementation with mangiferin and Luteolin in men","volume":"11","author":"Gelabert-Rebato","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.bbih.2025.101048_bib26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jaut.2018.03.001","article-title":"Mechanisms of neuropsychiatric lupus: the relative roles of the blood-cerebrospinal fluid barrier versus blood-brain barrier","volume":"91","author":"Gelb","year":"2018","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.bbih.2025.101048_bib27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.trsl.2016.03.013","article-title":"Mastocytosis in adulthood and neuropsychiatric disorders","volume":"174","author":"Georgin-Lavialle","year":"2016","journal-title":"Transl. Res."},{"issue":"8","key":"10.1016\/j.bbih.2025.101048_bib28","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11920-019-1062-8","article-title":"Obsessive-compulsive disorder: autoimmunity and neuroinflammation","volume":"21","author":"Gerentes","year":"2019","journal-title":"Curr. Psychiatry Rep."},{"issue":"3","key":"10.1016\/j.bbih.2025.101048_bib30","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1152\/physrev.00043.2007","article-title":"Histamine in the nervous system","volume":"88","author":"Haas","year":"2008","journal-title":"Physiol. Rev."},{"issue":"1","key":"10.1016\/j.bbih.2025.101048_bib31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41398-018-0143-5","article-title":"White matter abnormalities are also repeatedly present in patients with systemic mast cell activation syndrome","volume":"8","author":"Haenisch","year":"2018","journal-title":"Transl. Psychiatry"},{"issue":"6\u20137","key":"10.1016\/j.bbih.2025.101048_bib32","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.lfs.2013.01.010","article-title":"Investigation into mechanisms mediating the inhibitory effect of 1,4-benzodiazepines on mast cells by gene expression profiling","volume":"92","author":"Haenisch","year":"2013","journal-title":"Life Sci."},{"issue":"7","key":"10.1016\/j.bbih.2025.101048_bib33","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/mdc3.13506","article-title":"Tic disorders, anti-tic medications, and risk of atopy","volume":"9","author":"Hakimi","year":"2022","journal-title":"Mov. Disord. Clin. Pract."},{"issue":"5","key":"10.1016\/j.bbih.2025.101048_bib34","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/EDE.0000000000001219","article-title":"Trends in the risk of cognitive impairment in the United States, 1996-2014","volume":"31","author":"Hale","year":"2020","journal-title":"Epidemiology"},{"issue":"6","key":"10.1016\/j.bbih.2025.101048_bib35","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.2741\/e534","article-title":"Immuno- inflammatory markers of bipolar disorder: a review of evidence","volume":"4","author":"Hamdani","year":"2012","journal-title":"Front. Biosci. (Elite Ed)"},{"key":"10.1016\/j.bbih.2025.101048_bib36","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.neubiorev.2017.05.001","article-title":"Mast cells in neuroinflammation and brain disorders","volume":"79","author":"Hendriksen","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"3","key":"10.1016\/j.bbih.2025.101048_bib37","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1212\/WNL.0000000000011278","article-title":"Increasing out-of-pocket costs for neurologic care for privately insured patients","volume":"96","author":"Hill","year":"2021","journal-title":"Neurology"},{"issue":"1\u20133","key":"10.1016\/j.bbih.2025.101048_bib38","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejphar.2012.12.003","article-title":"Inhibitory effects of benzodiazepines on the adenosine A(2B) receptor mediated secretion of interleukin-8 in human mast cells","volume":"700","author":"Hoffmann","year":"2013","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.bbih.2025.101048_bib39","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3390\/ijms22020853","article-title":"Immunological dysfunction in Tourette syndrome and related disorders","volume":"22","author":"Hsu","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1\u20132","key":"10.1016\/j.bbih.2025.101048_bib40","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0091-3057(02)00708-6","article-title":"Experimental anxiety induced by histaminergics in mast cell-deficient and congenitally normal mice","volume":"72","author":"Ikarashi","year":"2002","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"1","key":"10.1016\/j.bbih.2025.101048_bib41","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13023-021-01747-y","article-title":"Neuropsychiatric, cognitive, and sexual impairment in mastocytosis patients","volume":"16","author":"Jendoubi","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.bbih.2025.101048_bib42","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3389\/fnins.2017.00703","article-title":"Mast cell activation in brain injury, stress, and post-traumatic stress disorder and Alzheimer's disease pathogenesis","volume":"11","author":"Kempuraj","year":"2017","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.bbih.2025.101048_bib43","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejphar.2018.07.011","article-title":"Evaluation of different classes of histamine H1 and H2 receptor antagonist effects on neuropathic nociceptive behavior following tibial nerve transection in rats","volume":"834","author":"Khalilzadeh","year":"2018","journal-title":"Eur. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.bbih.2025.101048_bib44","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1111\/ejn.15888","article-title":"Meningeal mast cell-mediated mechanisms of cholinergic system modulation in neurogenic inflammation underlying the pathophysiology of migraine","volume":"59","author":"Kilinc","year":"2024","journal-title":"Eur. J. Neurosci."},{"issue":"17","key":"10.1016\/j.bbih.2025.101048_bib45","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021002","article-title":"Mast cell activation disorder and postural orthostatic tachycardia syndrome: a clinical association","volume":"10","author":"Kohno","year":"2021","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.bbih.2025.101048_bib46","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12916-016-0712-5","article-title":"Immuno-psychiatry: an agenda for clinical practice and innovative research","volume":"14","author":"Leboyer","year":"2016","journal-title":"BMC Med."},{"issue":"7","key":"10.1016\/j.bbih.2025.101048_bib47","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/j.jaip.2019.03.039","article-title":"Omalizumab therapy for mast cell-mediator symptoms in patients with ISM, CM, MMAS, and MCAS","volume":"7","author":"Lemal","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"2","key":"10.1016\/j.bbih.2025.101048_bib48","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1017\/S1461145701002371","article-title":"Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS)","volume":"4","author":"Leonard","year":"2001","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.bbih.2025.101048_bib49","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1212\/WNL.0000000000004814","article-title":"Prospective study of restless legs syndrome and total and cardiovascular mortality among women","volume":"90","author":"Li","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.bbih.2025.101048_bib50","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.intimp.2018.11.009","article-title":"Berberine suppresses IL-33-induced inflammatory responses in mast cells by inactivating NF-\u03baB and p38 signaling","volume":"66","author":"Li","year":"2019","journal-title":"Int. Immunopharmacol."},{"issue":"5\u20136","key":"10.1016\/j.bbih.2025.101048_bib51","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000494761","article-title":"Neuroimmune and inflammatory signals in complex disorders of the central nervous system","volume":"25","author":"Liberman","year":"2018","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.bbih.2025.101048_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105947","article-title":"Zileuton ameliorates depressive-like behaviors, hippocampal neuroinflammation, apoptosis and synapse dysfunction in mice exposed to chronic mild stress","volume":"78","author":"Liu","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bbih.2025.101048_bib53","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/978-981-19-7376-5_13","article-title":"Obsessive-compulsive disorder, PANDAS, and Tourette syndrome: immuno-inflammatory disorders","volume":"1411","author":"Marazziti","year":"2023","journal-title":"Adv. Exp. Med. Biol."},{"issue":"6","key":"10.1016\/j.bbih.2025.101048_bib55","article-title":"Systemic mast cell activation disease variants and certain genetically determined comorbidities may be consequences of a common underlying epigenetic disease","volume":"163","author":"Molderings","year":"2022","journal-title":"Med. Hypotheses"},{"issue":"11","key":"10.1016\/j.bbih.2025.101048_bib56","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1007\/s00210-023-02545-y","article-title":"A survey of the currently known mast cell mediators with potential relevance for therapy of mast cell-induced symptoms","volume":"396","author":"Molderings","year":"2023","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"issue":"9","key":"10.1016\/j.bbih.2025.101048_bib57","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/00365520701245744","article-title":"Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder","volume":"42","author":"Molderings","year":"2007","journal-title":"Scand. J. Gastroenterol."},{"issue":"9","key":"10.1016\/j.bbih.2025.101048_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076241","article-title":"Familial occurrence of systemic mast cell activation disease","volume":"8","author":"Molderings","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.bbih.2025.101048_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026375","article-title":"Depression in patients with mastocytosis: prevalence, features, and effects of masitinib therapy","volume":"6","author":"Moura","year":"2011","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.bbih.2025.101048_bib60","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1177\/13591053211014583","article-title":"Depression, psychosocial correlates, and psychosocial resources in individuals with mast cell activation syndrome","volume":"27","author":"Nicoloro-SantaBarbara","year":"2022","journal-title":"J. Health Psychol."},{"issue":"4","key":"10.1016\/j.bbih.2025.101048_bib61","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.anai.2021.06.014","article-title":"Coping, social support, and anxiety in people with mast cell disorders","volume":"127","author":"Nicoloro-SantaBarbara","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"2","key":"10.1016\/j.bbih.2025.101048_bib62","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/biomedicines5020016","article-title":"Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia","volume":"5","author":"Parkitny","year":"2017","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.bbih.2025.101048_bib63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood-brain barrier: bottleneck in brain drug development","volume":"2","author":"Partridge","year":"2005","journal-title":"NeuroRx"},{"issue":"12","key":"10.1016\/j.bbih.2025.101048_bib64","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12319","article-title":"Cognitive, neuropsychiatric and neurological alterations in mastocytosis: a systematic review","volume":"13","author":"Sag\u00fces-Ses\u00e9","year":"2023","journal-title":"Clin. Transl. Allergy"},{"issue":"2","key":"10.1016\/j.bbih.2025.101048_bib65","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41583-021-00540-x","article-title":"The stressed synapse 2.0: pathophysiological mechanisms in stress-related neuropsychiatric disorders","volume":"23","author":"Sanacora","year":"2022","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bbih.2025.101048_bib66","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.neuropharm.2015.05.004","article-title":"The histamine H4-receptor and the central and peripheral nervous system: a critical analysis of the literature","volume":"106","author":"Schneider","year":"2016","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.bbih.2025.101048_bib67","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.amjms.2019.03.005","article-title":"Recognition and management of medication excipient reactivity in patients with mast cell activation syndrome","volume":"357","author":"Schofield","year":"2019","journal-title":"Am. J. Med. Sci."},{"issue":"4","key":"10.1016\/j.bbih.2025.101048_bib68","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/joim.12895","article-title":"The face of postural tachycardia syndrome - insights from a large cross-sectional online community-based survey","volume":"286","author":"Shaw","year":"2019","journal-title":"J. Intern. Med."},{"issue":"6","key":"10.1016\/j.bbih.2025.101048_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234001","article-title":"Increased blood-brain barrier hyperpermeability coincides with mast cell activation early under cuprizone administration","volume":"15","author":"Shelestak","year":"2020","journal-title":"PLoS One"},{"issue":"18","key":"10.1016\/j.bbih.2025.101048_bib70","doi-asserted-by":"crossref","first-page":"9859","DOI":"10.3390\/ijms25189859","article-title":"Histaminergic system activity in the central nervous system: the role in neurodevelopmental and neurodegenerative disorders","volume":"25","author":"Szukiewicz","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.bbih.2025.101048_bib71","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/exd.13288","article-title":"Neuroendocrinology of mast cells: challenges and controversies","volume":"26","author":"Theoharides","year":"2017","journal-title":"Exp. Dermatol."},{"issue":"4","key":"10.1016\/j.bbih.2025.101048_bib72","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.anai.2020.07.007","article-title":"The impact of psychological stress on mast cells","volume":"125","author":"Theoharides","year":"2020","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"1","key":"10.1016\/j.bbih.2025.101048_bib73","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbadis.2010.12.017","article-title":"Mast cell activation and autism","volume":"1822","author":"Theoharides","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"issue":"2","key":"10.1016\/j.bbih.2025.101048_bib74","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/039463201202500201","article-title":"A case series of a luteolin formulation (NeuroProtek\u00ae) in children with autism spectrum disorders","volume":"25","author":"Theoharides","year":"2012","journal-title":"Int. J. Immunopathol. Pharmacol."},{"issue":"1","key":"10.1016\/j.bbih.2025.101048_bib75","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bbadis.2010.12.014","article-title":"Mast cells and inflammation","volume":"1822","author":"Theoharides","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbih.2025.101048_bib76","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejphar.2015.03.086","article-title":"Mast cells, brain inflammation and autism","volume":"778","author":"Theoharides","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbih.2025.101048_bib77","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3389\/fncel.2019.00353","article-title":"Mast cells, neuroinflammation and pain in fibromyalgia syndrome","volume":"13","author":"Theoharides","year":"2019","journal-title":"Front. Cell. Neurosci."},{"issue":"4","key":"10.1016\/j.bbih.2025.101048_bib78","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.anai.2023.10.032","article-title":"Mast cells in the autonomic nervous system and potential role in disorders with dysautonomia and neuroinflammation","volume":"132","author":"Theoharides","year":"2024","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"8","key":"10.1016\/j.bbih.2025.101048_bib79","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1159\/000537752","article-title":"Luteolin is more potent than Cromolyn in their ability to inhibit mediator release from cultured human mast cells","volume":"185","author":"Tsilioni","year":"2024","journal-title":"Int. Arch. Allergy Immunol."},{"issue":"1","key":"10.1016\/j.bbih.2025.101048_bib80","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/brain\/awad283","article-title":"Review of the role of the endogenous opioid and melanocortin systems in the restless legs syndrome","volume":"147","author":"Walters","year":"2024","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.bbih.2025.101048_bib81","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2500\/aap.2021.42.210022","article-title":"The relationship between mast cell activation syndrome, postural tachycardia syndrome, and Ehlers-Danlos syndrome","volume":"42","author":"Wang","year":"2021","journal-title":"Allergy Asthma Proc."},{"issue":"10","key":"10.1016\/j.bbih.2025.101048_bib82","article-title":"The impact of vitamin D on neuropsychiatric disorders","volume":"15","author":"Wassif","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.bbih.2025.101048_bib83","series-title":"Chapter 3; Low Dose Naltrexone and Gut Health","first-page":"35","article-title":"The LDN book","volume":"vol 2","author":"Weinstock","year":"2020"},{"issue":"4","key":"10.1016\/j.bbih.2025.101048_bib84","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.smrv.2011.09.003","article-title":"Restless legs syndrome--theoretical roles of inflammatory and immune mechanisms","volume":"16","author":"Weinstock","year":"2012","journal-title":"Sleep Med. Rev."},{"key":"10.1016\/j.bbih.2025.101048_bib85","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-221405","article-title":"Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin, and antibiotic treatment","author":"Weinstock","year":"2018","journal-title":"BMJ Case Rep."},{"issue":"3","key":"10.1016\/j.bbih.2025.101048_bib86","doi-asserted-by":"crossref","first-page":"401","DOI":"10.5664\/jcsm.8216","article-title":"Restless legs syndrome is associated with mast cell activation syndrome","volume":"16","author":"Weinstock","year":"2020","journal-title":"J. Clin. Sleep Med."},{"key":"10.1016\/j.bbih.2025.101048_bib87","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ijid.2021.09.043","article-title":"Mast cell activation symptoms are prevalent in Long-COVID","volume":"112","author":"Weinstock","year":"2021","journal-title":"Int. J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.bbih.2025.101048_bib88","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s10620-020-06264-9","article-title":"Mast cell activation syndrome: a primer for the gastroenterologist","volume":"66","author":"Weinstock","year":"2021","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.bbih.2025.101048_bib89","first-page":"92","article-title":"Tinnitus in mast cell activation syndrome: a prospective survey of 114 patients","volume":"4","author":"Weinstock","year":"2021","journal-title":"J. Otolaryngol. Neurotol. Res."},{"issue":"11","key":"10.1016\/j.bbih.2025.101048_bib90","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.3390\/jpm13111562","article-title":"Neuropsychiatric manifestations of mast cell activation syndrome and response to mast-cell-directed treatment: a case series","volume":"13","author":"Weinstock","year":"2023","journal-title":"J. Personalized Med."},{"issue":"6","key":"10.1016\/j.bbih.2025.101048_bib91","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000001383","article-title":"Imatinib and trigger avoidance for mast cell activation syndrome presenting with attacks of abdominal pain, nausea, vomiting, and diarrhea","volume":"11","author":"Weinstock","year":"2024","journal-title":"ACG Case Rep. J."},{"issue":"1","key":"10.1016\/j.bbih.2025.101048_bib92","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s10194-019-0984-1","article-title":"Histamine and migraine revisited: mechanisms and possible drug targets","volume":"20","author":"Worm","year":"2019","journal-title":"J. Headache Pain"},{"issue":"5","key":"10.1016\/j.bbih.2025.101048_bib93","article-title":"Fibromyalgia and depression: a literature review of their shared aspects","volume":"14","author":"Yepez","year":"2022","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.bbih.2025.101048_bib94","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1478-811X-11-13","article-title":"The 1,4-benzodiazepine Ro5-4864 (4-chlorodiazepam) suppresses multiple pro-inflammatory mast cell effector functions","volume":"11","author":"Yousefi","year":"2013","journal-title":"Cell Commun. Signal."},{"issue":"3","key":"10.1016\/j.bbih.2025.101048_bib95","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jaip.2023.11.041","article-title":"Low prevalence of idiopathic mast cell activation syndrome among 703 patients with suspected mast cell disorders","volume":"12","author":"Zaghmout","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.bbih.2025.101048_bib96","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3389\/fimmu.2012.00169","article-title":"Role of female sex hormones, estradiol, and progesterone, in mast cell behavior","volume":"3","author":"Zierau","year":"2012","journal-title":"Front. Immunol."}],"container-title":["Brain, Behavior, & Immunity - Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666354625001061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666354625001061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T18:19:24Z","timestamp":1758133164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666354625001061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":94,"alternative-id":["S2666354625001061"],"URL":"https:\/\/doi.org\/10.1016\/j.bbih.2025.101048","relation":{},"ISSN":["2666-3546"],"issn-type":[{"value":"2666-3546","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence and treatment response of neuropsychiatric disorders in mast cell activation syndrome","name":"articletitle","label":"Article Title"},{"value":"Brain, Behavior, & Immunity - Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbih.2025.101048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101048"}}